Italia markets open in 7 hours 32 minutes

Abeona Therapeutics Inc. (ABEO)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
1,18000,0000 (0,00%)
Alla chiusura: 4:00PM EDT
1,1900 0,01 (0,85%)
Dopo ore: 06:36PM EDT

Abeona Therapeutics Inc.

1330 Avenue of the Americas
33rd Floor
New York, NY 10019
United States
646 813 4701
http://www.abeonatherapeutics.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno76

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Michael AmorosoPres, CEO & Director571,92kN/D1978
Mr. Edward G. CarrSr. VP, CFO & Chief Accounting Officer437,4kN/D1969
Mr. Brian Kevany Ph.D.VP & Chief Technical OfficerN/DN/DN/D
Mr. Gregory GinVP of Investor Relations & Corp. CommunicationsN/DN/DN/D
Dr. Brendan M. O'Malley J.D., Ph.D.Sr. VP & Gen. CounselN/DN/DN/D
Scott SantiamoDirector of Corp. CommunicationsN/DN/DN/D
Ms. Kristina MaximenkoVP of HRN/DN/DN/D
Dr. Vishwas Seshadri M.B.A., Ph.D.Sr. VP and Head of Research & Clinical Devel.N/DN/DN/D
Mr. Scott Nogi M.B.A.VP & Head of Bus. OperationN/DN/DN/D
Sofia WarnerSr. Director of Investor RelationsN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York.

Governance aziendale

L'ISS Governance QualityScore di Abeona Therapeutics Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.